CDKN2B-AS1 and osteosarcoma: Having determined that the CpGs sites associated with later bone outcomes may have functional relevance for ANRIL promoter activity in osteosarcoma cells, we next investigated the effect of perturbing ANRIL expression in SaOS‐2 cells.